Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- Economic Survey 2024-25 highlights need for reskilling as AI reshapes India’s labour market
- Refund for booked event ticket: Now Zomato allows you to sell your ticket, will other event booking platforms follow?
- Govt may defer Air India sale, reduce debt to sweeten the deal
- Budget Comment – Primus Partners